| Nov 5 |
Novo Nordisk Q3 Preview: Will $285 Million Weight Loss Bet Offset Bearish Charts?
|
| Nov 5 |
Ascendis Pharma and Novo Nordisk Join Forces
|
| Nov 5 |
Ascendis Pharma granted Novo exclusive worldwide license to TransCon platform
|
| Nov 4 |
Ozempic maker Novo Nordisk is working on a once-monthly weight-loss drug
|
| Nov 4 |
Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug
|
| Nov 4 |
Ascendis, Novo Nordisk to Develop, Commercialize Products in Metabolic, Cardiovascular Diseases
|
| Nov 4 |
Novo Nordisk, Ascendis partner to advance once-monthly obesity drug candidate
|
| Nov 4 |
Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases
|
| Oct 16 |
Ascendis Pharma ticks higher amid chatter it cancelled from upcoming conference
|
| Oct 8 |
3 Oversold Stocks with Big RSI Rebound Potential
|
